In-vivo biodistribution and safety of 99mTc-LLP2A-hynic in canine non-hodgkin lymphoma

Allison Zwingenberger, Michael S Kent, Ruiwu Liu, David L. Kukis, Erik R Wisner, Sally J. DeNardo, Sandra L. Taylor, Xiucui Chen, Kit Lam

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Theranostic agents are critical for improving the diagnosis and treatment of non-Hodgkin Lymphoma (NHL). The peptidomimetic LLP2A is a novel peptide receptor radiotherapy candidate for treating NHL that expresses the activated α4β1 integrin. Tumor-bearing dogs are an excellent model of human NHL with similar clinical characteristics, behavior, and compressed clinical course. Canine in vivo imaging studies will provide valuable biodistribution and affinity information that reflects a diverse clinical population of lymphoma. This may also help to determine potential dose-limiting radiotoxicity to organs in human clinical trials. To validate this construct in a naturally occurring model of NHL, we performed in-vivo molecular targeted imaging and biodistribution in 3 normal dogs and 5 NHL bearing dogs. 99mTc-LLP2A-HYNIC-PEG and 99mTc-LLP2A-HYNIC were successfully synthesized and had very good labeling efficiency and radiochemical purity. 99mTc-LLP2A-HYNIC and 99mTc-LLP2A-HYNIC-PEG had biodistribution in keeping with their molecular size, with 99mTc-LLP2A-HYNIC-PEG remaining longer in the circulation, having higher tissue uptake, and having more activity in the liver compared to 99mTc-LLP2A-HYNIC. 99mTc-LLP2A-HYNIC was mainly eliminated through the kidneys with some residual activity. Radioactivity was reduced to near-background levels at 6 hours after injection. In NHL dogs, tumor showed moderately increased activity over background, with tumor activity in B-cell lymphoma dogs decreasing after chemotherapy. This compound is promising in the development of targeted drug-delivery radiopharmaceuticals and may contribute to translational work in people affected by non-Hodgkin lymphoma.

Original languageEnglish (US)
Article numbere34404
JournalPLoS One
Volume7
Issue number4
DOIs
StatePublished - Apr 24 2012

Fingerprint

non-Hodgkin lymphoma
Bearings (structural)
Non-Hodgkin's Lymphoma
Polyethylene glycols
Canidae
Tumors
Safety
dogs
Dogs
Peptidomimetics
Imaging techniques
Chemotherapy
Peptide Receptors
Radiopharmaceuticals
Radioactivity
Radiotherapy
Integrins
Liver
Labeling
lymphoma

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

In-vivo biodistribution and safety of 99mTc-LLP2A-hynic in canine non-hodgkin lymphoma. / Zwingenberger, Allison; Kent, Michael S; Liu, Ruiwu; Kukis, David L.; Wisner, Erik R; DeNardo, Sally J.; Taylor, Sandra L.; Chen, Xiucui; Lam, Kit.

In: PLoS One, Vol. 7, No. 4, e34404, 24.04.2012.

Research output: Contribution to journalArticle

Zwingenberger, Allison ; Kent, Michael S ; Liu, Ruiwu ; Kukis, David L. ; Wisner, Erik R ; DeNardo, Sally J. ; Taylor, Sandra L. ; Chen, Xiucui ; Lam, Kit. / In-vivo biodistribution and safety of 99mTc-LLP2A-hynic in canine non-hodgkin lymphoma. In: PLoS One. 2012 ; Vol. 7, No. 4.
@article{b0455c0057f9494f95c2224a90c6cde9,
title = "In-vivo biodistribution and safety of 99mTc-LLP2A-hynic in canine non-hodgkin lymphoma",
abstract = "Theranostic agents are critical for improving the diagnosis and treatment of non-Hodgkin Lymphoma (NHL). The peptidomimetic LLP2A is a novel peptide receptor radiotherapy candidate for treating NHL that expresses the activated α4β1 integrin. Tumor-bearing dogs are an excellent model of human NHL with similar clinical characteristics, behavior, and compressed clinical course. Canine in vivo imaging studies will provide valuable biodistribution and affinity information that reflects a diverse clinical population of lymphoma. This may also help to determine potential dose-limiting radiotoxicity to organs in human clinical trials. To validate this construct in a naturally occurring model of NHL, we performed in-vivo molecular targeted imaging and biodistribution in 3 normal dogs and 5 NHL bearing dogs. 99mTc-LLP2A-HYNIC-PEG and 99mTc-LLP2A-HYNIC were successfully synthesized and had very good labeling efficiency and radiochemical purity. 99mTc-LLP2A-HYNIC and 99mTc-LLP2A-HYNIC-PEG had biodistribution in keeping with their molecular size, with 99mTc-LLP2A-HYNIC-PEG remaining longer in the circulation, having higher tissue uptake, and having more activity in the liver compared to 99mTc-LLP2A-HYNIC. 99mTc-LLP2A-HYNIC was mainly eliminated through the kidneys with some residual activity. Radioactivity was reduced to near-background levels at 6 hours after injection. In NHL dogs, tumor showed moderately increased activity over background, with tumor activity in B-cell lymphoma dogs decreasing after chemotherapy. This compound is promising in the development of targeted drug-delivery radiopharmaceuticals and may contribute to translational work in people affected by non-Hodgkin lymphoma.",
author = "Allison Zwingenberger and Kent, {Michael S} and Ruiwu Liu and Kukis, {David L.} and Wisner, {Erik R} and DeNardo, {Sally J.} and Taylor, {Sandra L.} and Xiucui Chen and Kit Lam",
year = "2012",
month = "4",
day = "24",
doi = "10.1371/journal.pone.0034404",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - In-vivo biodistribution and safety of 99mTc-LLP2A-hynic in canine non-hodgkin lymphoma

AU - Zwingenberger, Allison

AU - Kent, Michael S

AU - Liu, Ruiwu

AU - Kukis, David L.

AU - Wisner, Erik R

AU - DeNardo, Sally J.

AU - Taylor, Sandra L.

AU - Chen, Xiucui

AU - Lam, Kit

PY - 2012/4/24

Y1 - 2012/4/24

N2 - Theranostic agents are critical for improving the diagnosis and treatment of non-Hodgkin Lymphoma (NHL). The peptidomimetic LLP2A is a novel peptide receptor radiotherapy candidate for treating NHL that expresses the activated α4β1 integrin. Tumor-bearing dogs are an excellent model of human NHL with similar clinical characteristics, behavior, and compressed clinical course. Canine in vivo imaging studies will provide valuable biodistribution and affinity information that reflects a diverse clinical population of lymphoma. This may also help to determine potential dose-limiting radiotoxicity to organs in human clinical trials. To validate this construct in a naturally occurring model of NHL, we performed in-vivo molecular targeted imaging and biodistribution in 3 normal dogs and 5 NHL bearing dogs. 99mTc-LLP2A-HYNIC-PEG and 99mTc-LLP2A-HYNIC were successfully synthesized and had very good labeling efficiency and radiochemical purity. 99mTc-LLP2A-HYNIC and 99mTc-LLP2A-HYNIC-PEG had biodistribution in keeping with their molecular size, with 99mTc-LLP2A-HYNIC-PEG remaining longer in the circulation, having higher tissue uptake, and having more activity in the liver compared to 99mTc-LLP2A-HYNIC. 99mTc-LLP2A-HYNIC was mainly eliminated through the kidneys with some residual activity. Radioactivity was reduced to near-background levels at 6 hours after injection. In NHL dogs, tumor showed moderately increased activity over background, with tumor activity in B-cell lymphoma dogs decreasing after chemotherapy. This compound is promising in the development of targeted drug-delivery radiopharmaceuticals and may contribute to translational work in people affected by non-Hodgkin lymphoma.

AB - Theranostic agents are critical for improving the diagnosis and treatment of non-Hodgkin Lymphoma (NHL). The peptidomimetic LLP2A is a novel peptide receptor radiotherapy candidate for treating NHL that expresses the activated α4β1 integrin. Tumor-bearing dogs are an excellent model of human NHL with similar clinical characteristics, behavior, and compressed clinical course. Canine in vivo imaging studies will provide valuable biodistribution and affinity information that reflects a diverse clinical population of lymphoma. This may also help to determine potential dose-limiting radiotoxicity to organs in human clinical trials. To validate this construct in a naturally occurring model of NHL, we performed in-vivo molecular targeted imaging and biodistribution in 3 normal dogs and 5 NHL bearing dogs. 99mTc-LLP2A-HYNIC-PEG and 99mTc-LLP2A-HYNIC were successfully synthesized and had very good labeling efficiency and radiochemical purity. 99mTc-LLP2A-HYNIC and 99mTc-LLP2A-HYNIC-PEG had biodistribution in keeping with their molecular size, with 99mTc-LLP2A-HYNIC-PEG remaining longer in the circulation, having higher tissue uptake, and having more activity in the liver compared to 99mTc-LLP2A-HYNIC. 99mTc-LLP2A-HYNIC was mainly eliminated through the kidneys with some residual activity. Radioactivity was reduced to near-background levels at 6 hours after injection. In NHL dogs, tumor showed moderately increased activity over background, with tumor activity in B-cell lymphoma dogs decreasing after chemotherapy. This compound is promising in the development of targeted drug-delivery radiopharmaceuticals and may contribute to translational work in people affected by non-Hodgkin lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=84860182457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860182457&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0034404

DO - 10.1371/journal.pone.0034404

M3 - Article

C2 - 22545083

AN - SCOPUS:84860182457

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e34404

ER -